Citadel Advisors
INKT icon

Citadel Advisors’s MiNK Therapeutics INKT Stock Holding History

Citadel Advisors’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180K Buy
+15,440
New +$180K ﹤0.01% 12179
2024
Q2 		– Sell
-2,081
Closed -$18.9K – 14820
2024
Q1 		$18.9K Sell
2,081
-2,133
-51% -$19.8K ﹤0.01% 13049
2023
Q4 		$45.3K Buy
+4,214
New +$44K ﹤0.01% 11882
2023
Q3 		– Sell
-5,105
Closed -$107K – 14668
2023
Q2 		$107K Buy
+5,105
New +$102K ﹤0.01% 10829

Other funds holding INKT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $151M AUM

Citadel Advisors's INKT Position: Q2 2026 in Review

Citadel Advisors opened a new position in MiNK Therapeutics (INKT) in Q2 2026: 15,440 shares worth $180K. The stake represents ﹤0.01% of the portfolio and ranks #12179 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in INKT as recently as Q1 2024.

Citadel Advisors first reported a position in INKT in Q2 2023 and has held it in 4 quarters since. 27 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • Citadel Advisors held 15,440 shares of MiNK Therapeutics worth $180K as of Q2 2026.
  • MiNK Therapeutics was a new Citadel Advisors position in Q2 2026.
  • MiNK Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12179 holding.
  • Citadel Advisors first reported a position in MiNK Therapeutics in Q2 2023 and has held it in 4 quarters since.
  • 27 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.